Effects of recombinant human bone morphogenetic protein-2 on the proliferation of breast cancer MCF-7 cells

doi:10.3969/j.issn.2095-4344.0578

Abstract

Abstract:

BACKGROUND: Clinical application of recombinant human bone morphogenetic protein-2 (rhBMP-2) has been found to increase the risk for malignant tumors, but the effect of rhBMP-2 on the proliferation of breast cancer MCF-7 cells and the underlying mechanism remain unclear.
OBJECTIVE: To explore the effects of rhBMP-2 on the proliferation of breast cancer MCF-7 cells and the underlying mechanism in vivo and in vitro.
METHODS: In vitro study: cell proliferation of MCF-7 under different concentrations of rhBMP-2 was determined by MTT assay and flow cytometry in serum-free condition. The cell cycle was detected by flow cytometry. The expression levels of p21 and cyclin E were detected by real-time PCR. The protein levels of p21, cyclin E and phosphorylation of PI3K/Akt were tested by western blot and real-time PCR. In vivo study: fourteen 6-week-old female nude mice were divided into two groups: experimental group (subcutaneous injection of rhBMP-2 plus MCF-7 cells), control group (subcutaneous injection of the same volume of MCF-7 cells).
RESULTS AND CONCLUSION: In vitro study: rhBMP-2 markedly inhibited the proliferation of MCF-7 cells in serum-free condition. After 24-hour treatment, rhBMP-2 could increase the G1 cell ratio. rhBMP-2 could significantly increase the expression of p21 as well as significantly inhibit the expression of cyclin E and phosphorylation in the PI3K/Akt signaling pathway. In vivo study: the volume of subcutaneous tumor in the experimental group was smaller than that in the control group. Immunohistochemistry revealed that rhBMP-2 could significantly decrease the expression level of ki-67 in tumor tissues. Our study suggests that rhBMP-2 has significantly suppressive effect on the proliferation of breast cancer MCF-7 cells via PI3K/Akt pathway in vitro and in vivo. Therefore, we can provide the basic science data to avoid risks of breast cancer and to support the utilization of rhBMP-2 in the management of spinal fusion, treatment of bone ununion and other orthopedic disorders.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Bone Morphogenetic Proteins, Neoplasms, Cell Proliferation, Tissue Engineering

CLC Number:

R459.9

Liu Shuzhong, Lao Lifeng. Effects of recombinant human bone morphogenetic protein-2 on the proliferation of breast cancer MCF-7 cells[J]. Chinese Journal of Tissue Engineering Research, 2019, 23(3): 458-463.

Figures/Tables 2

References

[1] Urist MR. Bone: formation by autoinduction. Science. 1965;150 (3698):893-899.

[2] Salazar VS, Gamer LW, Rosen V. BMP signalling in skeletal development, disease and repair. Nat Rev Endocrinol. 2016;12(4): 203-221.

[3] Kang MH, Kang HN, Kim JL, et al. Inhibition of PI3 kinase/Akt pathway is required for BMP2-induced EMT and invasion. Oncol Rep. 2009;22(3):525-534.

[4] Lao L, Shen J, Tian H, et al. Secreted phosphoprotein 24kD (Spp24) inhibits growth of hepatocellular carcinoma in vivo. Environ Toxicol Pharmacol. 2017;51:51-55.

[5] Li CS, Tian H, Zou M, et al. Secreted phosphoprotein 24 kD (Spp24) inhibits growth of human pancreatic cancer cells caused by BMP-2. Biochem Biophys Res Commun. 2015;466(2):167-172.

[6] Yu JS, Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 2016;143(17):3050-3060.

[7] Faundez A, Tournier C, Garcia M, et al. Bone morphogenetic protein use in spine surgery-complications and outcomes: a systematic review. Int Orthop. 2016;40(6):1309-1319.

[8] James AW, LaChaud G, Shen J, et al. A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2. Tissue Eng Part B Rev. 2016;22(4):284-297.

[9] Bodalia PN, Balaji V, Kaila R, et al. Effectiveness and safety of recombinant human bone morphogenetic protein-2 for adults with lumbar spine pseudarthrosis following spinal fusion surgery: A systematic review. Bone Joint Res. 2016;5(4):145-152.

[10] Ghosh-Choudhury N, Woodruff K, Qi W, et al. Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. Biochem Biophys Res Commun. 2000;272(3):705-711.

[11] Katsuno Y, Hanyu A, Kanda H, et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene. 2008;27(49): 6322-6333.

[12] Ye S, Park BH, Song KJ, et al. In vivo inhibition of bone morphogenetic protein-2 on breast cancer cell growth. Spine (Phila Pa 1976). 2013;38(3):E143-150.

[13] Vavken J, Mameghani A, Vavken P, et al. Complications and cancer rates in spine fusion with recombinant human bone morphogenetic protein-2 (rhBMP-2). Eur Spine J. 2016;25(12): 3979-3989.

[14] Tannoury CA, An HS2. Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J. 2014;14(3):552-559.

[15] Young A, Mirarchi A. Soft Tissue Swelling Associated with the Use of Recombinant Human Bone Morphogenetic Protein-2 in Long Bone Non-unions. J Orthop Case Rep. 2015;5(3):18-21.

[16] Malham GM, Giles GG, Milne RL, et al. Bone Morphogenetic Proteins in Spinal Surgery: What Is the Fusion Rate and Do They Cause Cancer? Spine (Phila Pa 1976). 2015;40(22):1737-1742.

[17] Skovrlj B, Koehler SM, Anderson PA, et al. Association Between BMP-2 and Carcinogenicity. Spine (Phila Pa 1976). 2015;40(23): 1862-1871.

[18] Wozney JM, Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop Relat Res. 1998;(346):26-37.

[19] Wang Y, He T, Liu J, et al. Synergistic effects of overexpression of BMP?2 and TGF?β3 on osteogenic differentiation of bone marrow mesenchymal stem cells. Mol Med Rep. 2016;14(6):5514-5520.

[20] Zheng Y, Wang X, Wang H, et al. Bone morphogenetic protein 2 inhibits hepatocellular carcinoma growth and migration through downregulation of the PI3K/AKT pathway. Tumour Biol. 2014; 35(6):5189-5198.

[21] Zhao X, Wang Q, Yang S, et al. Quercetin inhibits angiogenesis by targeting calcineurin in the xenograft model of human breast cancer. Eur J Pharmacol. 2016;781:60-68.

[22] Noël A, De Pauw-Gillet MC, Purnell G, et al. Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br J Cancer. 1993;68(5): 909-915.

[23] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-132.

[24] Fontanella C, Fanotto V, Rihawi K, et al. Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. Clin Exp Metastasis. 2015;32(8):819-833.

[25] Sciubba DM, Goodwin CR, Yurter A, et al. A Systematic Review of Clinical Outcomes and Prognostic Factors for Patients Undergoing Surgery for Spinal Metastases Secondary to Breast Cancer. Global Spine J. 2016;6(5):482-496.